Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure

(2013) Kim Fox et al.   AMERICAN HEART JOURNAL

Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure

(2013) Finlay A. McAlister   ANNALS OF INTERNAL MEDICINE

β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

(2012) Sripal Bangalore et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?

(2012) Karl Swedberg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Heart rate: a forgotten link in coronary artery disease?

(2011) Kim M. Fox et al.   Nature Reviews Cardiology

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

(2010) Karl Swedberg et al.   LANCET

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

(2010) Michael Böhm et al.   LANCET

Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial

(2009) K. Fox et al.   EUROPEAN HEART JOURNAL

Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial

(2009) J.-C. Tardif et al.   EUROPEAN HEART JOURNAL

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

(2008) Kim Fox et al.   LANCET

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

(2008) Kim Fox et al.   LANCET